- Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
-
Kim DY
- KMID: 2413114
- Clin Mol Hepatol.
- 2017 Jun;23(2):123-124.
- doi: 10.3350/cmh.2017.0107
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Advances in the treatment of hepatocellular carcinoma
-
Lee JS
- KMID: 2258430
- Korean J Med.
- 2009 Sep;77(3):290-297.
There have been recent advances in the treatment of hepatocellular carcinoma (HCC). There has been a clear change in the presentation of HCC, with an increased detection of tumors -
- CITED
-
- Close
- SHARE
-
- Close
- Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin in a Patient with Hepatocellular Carcinoma
-
Choi MK, Woo HY, Heo J, Cho M, Kim GH, Song GA, Kim MB
- KMID: 2171884
- Ann Dermatol.
- 2011 Dec;23(Suppl 3):S404-S407.
- doi: 10.5021/ad.2011.23.S3.S404
This is the first case report to describe a 44-year-old woman with a history of advanced hepatocellular carcinoma who developed toxic epidermal necrolysis (TEN) clinically after taking 400 mg sorafenib... -
- CITED
-
- Close
- SHARE
-
- Close
- Cutaneous Adverse Effects Associated with Sorafenib Therapy (Nexavar(R), BAY 43-9006)
-
Park JH, Kim S, Choi SC, Lee ES, Yang JM
- KMID: 2087929
- Korean J Dermatol.
- 2008 Jan;46(1):141-143.
Sorafenib (Nexavar(R), BAY 43-9006) is a new oral multi-targeted tyrosine kinase inhibitor developed to delay disease progression in advanced solid organ malignancies and metastatic melanoma. Among the many reported toxicities... -
- CITED
-
- Close
- SHARE
-
- Close
- New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
-
Woo HY, Heo J
- KMID: 2164360
- Clin Mol Hepatol.
- 2015 Jun;21(2):115-121.
- doi: 10.3350/cmh.2015.21.2.115
Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of... -
- CITED
-
- Close
- SHARE
-
- Close
- Sorafenib (Nexavar(R), BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema
-
Kim DH, Son IP, Lee JW, Lee HI, Kim BJ, Kim MN
- KMID: 2171970
- Ann Dermatol.
- 2011 Feb;23(1):119-122.
- doi: 10.5021/ad.2011.23.1.119
Sorafenib (Nexavar(R), BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has recently been approved for the treatment of metastatic renal cell carcinoma. It is also used to delay... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura
-
Kim EJ, Choi YM, Lee SW, Ha YJ, Lee JL
- KMID: 2267896
- Korean J Med.
- 2013 Feb;84(2):303-307.
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP-HUS) is an acute condition with abnormalities of multiple organ systems. It is characterized by microangiopathic hemolytic anemia and thrombocytopenia. Several chemotherapeutic agents... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of in vitro apoptosis induced by virulent Korean isolate of classical swine fever virus in peripheral blood B cell line
-
Kim SM, Lim SI, Song JY, Hyun BH
- KMID: 1431986
- Korean J Vet Res.
- 2012 Dec;52(4):259-262.
Classical swine fever (CSF) is a highly contagious disease among swine that has an important economic impact on worldwide. One clinical symptom of CSF is leukopenia, in particular lymphopenia, which... -
- CITED
-
- Close
- SHARE
-
- Close
- Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report
-
Lee SR, Kim YM, Jung JY, Kim HJ, Kim DH, Park KW, Lee SI
- KMID: 2264575
- Korean J Med.
- 2012 Oct;83(4):520-524.
Everolimus, an inhibitor of the mammalian target of rapamycin, is an active agent against metastatic renal cell carcinoma. Treatment with everolimus prolongs progression-free survival in patients with clear cell-type renal... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Leukocytoclastic Vasculitis after Use of Sorafenib (Nexavar(R))
-
Kim HJ, Kim JH, Kim JB, Kim HK, Ko YS, Joh OJ, Lee JS, Song KY
- KMID: 2248297
- Korean J Dermatol.
- 2008 May;46(5):648-651.
Sorafenib (Nexavar(R)) is an oral multikinase inhibitor that was recently approved for use in metastatic renal cancer. It is currently undergoing investigation for the treatment of locally advanced renal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Sorafenib-Induced Interstitial Pneumonitis in a Patient with Hepatocellular Carcinoma: A Case Report
-
Myung HJ, Jeong SH, Kim JW, Kim HS, Jang JH, Yoon HI, Kim JS
- KMID: 2167264
- Gut Liver.
- 2010 Dec;4(4):543-546.
Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe. We treated a patient with... -
- CITED
-
- Close
- SHARE
-
- Close
- Diagnosis and Treatment of Gastrointestinal Stromal Tumor
-
Kang YK, Koo DH
- KMID: 2267783
- Korean J Med.
- 2013 Oct;85(4):341-353.
Gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors of the gastrointestinal tract, have represented an important advance in oncology field with the success of molecular targeted therapy.... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT
-
Yoon SY, Kim SY, Cho YH, Chung HW, So Y, Lee HM
- KMID: 2165986
- Cancer Res Treat.
- 2009 Jun;41(2):100-103.
We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to... -
- CITED
-
- Close
- SHARE
-
- Close
- Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction
-
Oh D, Park HC, Lim HY, Yoo BC
- KMID: 2051134
- Radiat Oncol J.
- 2013 Sep;31(3):171-174.
- doi: 10.3857/roj.2013.31.3.171
Sorafenib is a multi-targeted kinase inhibitor, which is the current standard treatment for advanced hepatocellular carcinoma (HCC). Only one case of radiation recall dermatitis (RRD) associated with sorafenib has been... -
- CITED
-
- Close
- SHARE
-
- Close
- Liver Abscess in Advanced Hepatocellular Carcinoma after Sorafenib Treatment
-
Shin SK, Jung YK, Yoon HH, Kwon OS, Kim YS, Choi DJ, Kim JH
- KMID: 1711306
- Korean J Gastroenterol.
- 2014 Jan;63(1):47-50.
- doi: 10.4166/kjg.2014.63.1.47
Hepatocellular carcinoma (HCC) is a critical global health issue and the third most common cause of cancer-related deaths worldwide. The majority of patients who present HCC are already at an... -
- CITED
-
- Close
- SHARE
-
- Close
- Newer treatments for advanced hepatocellular carcinoma
-
Song MJ, Bae SH
- KMID: 1792028
- Korean J Intern Med.
- 2014 Mar;29(2):149-155.
- doi: 10.3904/kjim.2014.29.2.149
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The only curative treatment modalities for HCC are surgery, percutaneous ablation, and liver transplantation. Unfortunately, the majority of patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Target Therapy for Hepatocellular Carcinoma
-
Yoon SK
- KMID: 2168205
- Hanyang Med Rev.
- 2012 May;32(2):118-125.
- doi: 10.7599/hmr.2012.32.2.118
Hepatocellular carcinoma (HCC) is a highly malignant tumor that has limited treatment options in its advanced state. The efficacy of current anti-cancer chemotherapy in advanced HCC has not been satisfactory,... -
- CITED
-
- Close
- SHARE
-
- Close
- High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma
-
Seo MS, Kim JK, Shim JY
- KMID: 2163643
- Yonsei Med J.
- 2015 Sep;56(5):1449-1452.
- doi: 10.3349/ymj.2015.56.5.1449
We report a case of regression of multiple pulmonary metastases, which originated from hepatocellular carcinoma after treatment with intravenous administration of high-dose vitamin C. A 74-year-old woman presented to the... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in systemic chemotherapy of hepatocellular carcinoma
-
Kim BH, Park JW
- KMID: 2193474
- J Korean Med Assoc.
- 2013 Nov;56(11):993-1000.
- doi: 10.5124/jkma.2013.56.11.993
Sorafenib, as the first approved molecularly targeted agent for hepatocellular carcinoma (HCC), has changed the treatment paradigm for patients with advanced HCC. Although a significant survival advantage has been achieved... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Hepatocellular Carcinoma with Portal Vein Thrombosis by Sorafenib Combined with Hepatic Arterial Infusion Chemotherapy
-
Yang MY, Jeong SW, Kim DK, Kim SG, Jang JY, Kim YS, Lee JS, Kim BS, Kim JH, Kim YJ
- KMID: 1974151
- Gut Liver.
- 2010 Sep;4(3):423-427.
Treatment with sorafenib prolongs both the median survival and time to progression by nearly 3 months in patients with advanced hepatocellular carcinoma. Although the effects of combining sorafenib therapy with... -
- CITED
-
- Close
- SHARE
-
- Close
